This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

Trial shows mistletoe extract does not increase survival in advanced pancreatic cancer

Trial shows mistletoe extract did not increase survival in advanced pancreatic cancer
Credit: Deutsches Ärzteblatt international (2024). DOI: 10.3238/arztebl.m2024.0080

The MISTRAL study, involving 290 patients with advanced pancreatic cancer, has investigated whether treatment with mistletoe extract (ME) in addition to standard treatment could help patients live longer. The result is that the treatment did not make any difference compared to placebo in how long the patients lived. The study is published in Deutsches Ärzteblatt international.

This national multicenter study ran between 2016 and 2022.

"We saw no difference in how long the patients lived or in terms of their overall quality of life when we added the ME treatment," says the leader of the study Kathrin Wode, specialist in oncology and palliative medicine, Department of Diagnostics and Intervention, Umeå University.

Previous studies have shown that ME treatment could help patients with live longer and improve their quality of life. But the results of the MISTRAL study were different.

"We were surprised that our results differed so much from previous studies. Of course, it would have been good news to find a positive result for survival in this disease.

An important difference compared to previous studies is that MISTRAL was a randomized double-blind study, i.e. with where neither the patients nor the knew who was given ME treatment or placebo. Despite this, some patients could have guessed that they were receiving the ME treatment due to reactions at the injection site, but this does not seem to have affected the results.

"Our results will be important for those caring for with advanced pancreatic cancer. Although we did not see any effect of the ME treatment in this study, the study did not show any risks associated with using it. Our study does not answer the question of whether ME treatment is effective for other tumors," says Kathrin Wode.

More information: Kathrin Wode et al, Mistletoe extract in patients with advanced pancreatic cancer: a double-blind, randomized, placebo-controlled trial (MISTRAL), Deutsches Ärzteblatt international (2024). DOI: 10.3238/arztebl.m2024.0080

Provided by Umea University
Citation: Trial shows mistletoe extract does not increase survival in advanced pancreatic cancer (2024, May 31) retrieved 16 July 2024 from https://medicalxpress.com/news/2024-05-trial-mistletoe-survival-advanced-pancreatic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

End-of-life systemic treatment for patients with advanced cancers does not improve survival, finds study

0 shares

Feedback to editors